Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/620400
Title:
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Authors:
Meyer, T.; Fox, R.; Ma, Y. T.; Ross, P. J.; James, M. W.; Sturgess, R.; Stubbs, C.; Stocken, D. D.; Wall, L.; Watkinson, Anthony; Hacking, N.; Evans, T. R. J.; Collins, P.; Hubner, R. A.; Cunningham, D.; Primrose, J. N.; Johnson, P. J.; Palmer, D. H.
Abstract:
Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo.
Citation:
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. 2017, 2 (8):565-575 Lancet Gastroenterol Hepatol
Publisher:
Elsevier
Journal:
The Lancet. Gastroenterology & Hepatology
Issue Date:
Aug-2017
URI:
http://hdl.handle.net/11287/620400
DOI:
10.1016/S2468-1253(17)30156-5
PubMed ID:
28648803
Additional Links:
https://linkinghub.elsevier.com/retrieve/pii/S2468-1253(17)30156-5
Note:
This article is freely available via Open Access. Click on Additional Link above to access the full-text via the publisher's site.
Type:
Journal Article
Language:
en
ISSN:
2468-1253
Appears in Collections:
Radiology Department; 2017 RD&E publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMeyer, T.en
dc.contributor.authorFox, R.en
dc.contributor.authorMa, Y. T.en
dc.contributor.authorRoss, P. J.en
dc.contributor.authorJames, M. W.en
dc.contributor.authorSturgess, R.en
dc.contributor.authorStubbs, C.en
dc.contributor.authorStocken, D. D.en
dc.contributor.authorWall, L.en
dc.contributor.authorWatkinson, Anthonyen
dc.contributor.authorHacking, N.en
dc.contributor.authorEvans, T. R. J.en
dc.contributor.authorCollins, P.en
dc.contributor.authorHubner, R. A.en
dc.contributor.authorCunningham, D.en
dc.contributor.authorPrimrose, J. N.en
dc.contributor.authorJohnson, P. J.en
dc.contributor.authorPalmer, D. H.en
dc.date.accessioned2017-09-18T12:41:27Z-
dc.date.available2017-09-18T12:41:27Z-
dc.date.issued2017-08-
dc.identifier.citationSorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. 2017, 2 (8):565-575 Lancet Gastroenterol Hepatolen
dc.identifier.issn2468-1253-
dc.identifier.pmid28648803-
dc.identifier.doi10.1016/S2468-1253(17)30156-5-
dc.identifier.urihttp://hdl.handle.net/11287/620400-
dc.description.abstractTransarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttps://linkinghub.elsevier.com/retrieve/pii/S2468-1253(17)30156-5en
dc.rightsArchived with thanks to The lancet. Gastroenterology & hepatologyen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.subjectWessex Classification Subject Headings::Gastroenterologyen
dc.titleSorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.en
dc.typeJournal Articleen
dc.identifier.journalThe Lancet. Gastroenterology & Hepatologyen
dc.description.noteThis article is freely available via Open Access. Click on Additional Link above to access the full-text via the publisher's site.en
dc.type.versionPublisheden

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.